REVIEW

Hyperkalemia in patients undergoing hemodialysis: Its pathophysiology and management

Shigeru Shibata1 | Shunya Uchida1,2

1Division of Nephrology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
2Department of Health Care, Teikyo Heisei University, Tokyo, Japan

Correspondence
Shigeru Shibata, Division of Nephrology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.
Email: shigeru.shibata@med.teikyo-u.ac.jp

Funding information
JSPS KAKENHI, Grant/Award Number: 19H03678

Abstract
Potassium is a major intracellular cation in the body, regulating membrane potential of excitable cells, such as cardiomyocytes and skeletal muscle cells. Because the kidney plays a critical role in controlling potassium balance, the elevation in serum potassium levels is one of the most common complications in patients with maintenance hemodialysis (MHD). In addition to reduced renal potassium excretion, the alteration in body potassium distribution owing to comorbid conditions may also contribute to dyskalemia. Besides potassium elimination through hemodialysis in MHD patients, accumulating data indicate the potential importance of extra-renal elimination involving the gastrointestinal system, which can be affected by the inhibitors of the renin-angiotensin-aldosterone system. In this article, the literature on potassium physiology in MHD patients is reviewed with an emphasis on the changes from individuals with normal kidney function. This article also summarizes the findings of recent studies on dietary control, dialysate prescription, and pharmacological therapy.

KEYWORDS
electrolyte homeostasis, extra-renal potassium secretion, hemodialysis, plant-based diet, renin-angiotensin-aldosterone system inhibitors

1 | INTRODUCTION

Potassium is the most abundant cation within cells, amounting to 3000–4000 mmol in the human adult body. Among its diverse roles, the ratio of extracellular to intracellular potassium concentration determines the resting membrane potential, regulating the function of excitable cells, such as cardiomyocytes and skeletal muscles. Because the dysregulation of extracellular potassium levels can potentially result in fatal outcomes by affecting the contractility of these cells, serum potassium concentration is strictly controlled in a very narrow range of 3.5–5 mmol/L.

The kidney plays a critical role in regulating serum potassium levels, and hyperkalemia is one of the most common complications in patients with CKD and end-stage kidney disease (ESKD) [1–3]. In addition to the reduced renal elimination of potassium, patients with kidney diseases often have multiple comorbidities that affect potassium homeostasis, including DM, metabolic acidosis, and cardiovascular diseases [4, 5]. Medications such as renin-angiotensin-aldosterone system (RAAS) inhibitors (especially mineralocorticoid receptor [MR] antagonists) and non-steroidal anti-inflammatory drugs further increase the risk of hyperkalemia [3, 6, 7]. As a result, the prevalence of hyperkalemia (serum potassium levels of 5.1 mmol/L or higher) is reported to be 25%–30% in CKD patients and in maintenance hemodialysis (MHD) patients [3, 4, 7]. In this article, we discuss physiological changes in potassium...
homeostasis in ESKD patients compared with healthy individuals, as well as recent advances in potassium management in MHD.

2 | OVERVIEW OF POTASSIUM HOMEOSTASIS IN HEALTHY INDIVIDUALS

Most of the potassium in the body is distributed within cells, such as skeletal muscle and liver, whereas only 2% is present in the extracellular fluid (Table 1). Body distribution (intracellular vs. extracellular) and the rate of excretion are the key factors that determine serum potassium levels. In the former process, the sodium-potassium-adenosine-triphosphatase (Na/K-ATPase) at the cell surface is responsible for the intracellular uptake of potassium in exchange for sodium. Several hormones, such as insulin, thyroid hormone, and epinephrine, facilitate potassium uptake into cells by stimulating the activity of Na/K-ATPase. In the latter process, the kidney excretes 80%–90% of the daily potassium intake, and the remainder is excreted through the gastrointestinal system. Recent studies have elucidated that the appropriate responses of the kidney to varied potassium intake are achieved through the coordinated action of distal convoluted tubule cells, collecting duct principal cells, intercalated cells, and the steroid hormone aldosterone. The current model indicates that aldosterone-mediated stimulation of the epithelial sodium channel in principal cells, along with the inactivation of the sodium chloride cotransporter (NCC) in the distal convoluted tubules and pendrin in intercalated cells, maximizes potassium secretion through renal outer medullary potassium (ROMK) channel [8, 9] and flow-induced potassium secretion through high conductance potassium (BK) channel [10]. In addition, as-yet-to-be-identified gut factors can also play important roles in renal adaptation to potassium [11].

Epidemiological studies have demonstrated that a high potassium intake in subjects with normal renal function is associated with favorable effects, such as reduction in salt sensitivity, blood pressure lowering, and prevention of cerebrovascular diseases [12–14]. These observations are explained by the renal and extra-renal effects of potassium, including suppression of NaCl reabsorption and modulation of sympathetic nerve activity and vascular function [15–17].

3 | CHANGES IN POTASSIUM REGULATION IN MHD PATIENTS

3.1 | Potassium removal during hemodialysis

One of the essential roles of hemodialysis is to maintain body potassium balance in ESKD patients. Sodium, which is mostly present in the extracellular fluid, is mainly removed via convection during hemodialysis, whereas approximately 85% of intradialytic potassium removal is achieved by diffusion [18], which is highly influenced by the serum-to-dialysate potassium gradient [19]. During the dialysis treatment, serum potassium levels typically decrease by 1 mmol/L in the first hour, followed by an additional decline of 1 mmol/L in the next 2 h, and a gradual decline toward a dialysate potassium concentration in the final hours [18, 20]. Given the intermittent nature of dialysis therapy, post-dialysis rebound of serum potassium levels occurs, caused by the shift of potassium from intracellular to extracellular compartments after the treatment. The decrease in serum potassium levels is attenuated by approximately 70% within the following 6 h after dialysis therapy [20, 21]. Considerable efforts have been made to elucidate the optimum dialysate potassium prescription, which will be discussed later.

3.2 | Extra-renal potassium secretion through the gastrointestinal system

Potassium removal in dialysis is typically approximately 70–100 mmol per session (210–300 mmol/week for

| TABLE 1 Changes in potassium balance in MHD patients |
|-----------------------------------------------|
| **Healthy subject** | **MHD patients** |
| Potassium intake | 50–100 mmol per day | Decreased |
| Extracellular potassium levels | 2% of total body potassium | Increased or unchanged |
| Intracellular potassium levels | 98% of total body potassium | Unchanged or decreased |
| Renal potassium excretion | 80%–90% of daily potassium intake | Decreased or none |
| Fecal potassium excretion | ~10% of daily potassium intake | Increased |
| Potassium removal by hemodialysis | None | 70–100 mmol per session |

Abbreviation: MHD, maintenance hemodialysis.
typical three times weekly hemodialysis) [18]. Therefore, extra-renal elimination is considered to be necessary to achieve potassium balance in MHD patients who have a potassium intake that exceeds this level (Figure 1). Several studies have shown that potassium excretion through the gastrointestinal tract is increased in ESKD patients [22, 23] (Table 1). For example, Hayes et al. conducted a metabolic balance study in 21 patients with CKD, including patients undergoing hemodialysis and found that creatinine clearance below 5 ml/min is associated with a marked increase in fecal potassium excretion, with the total amount exceeding 30% of the daily potassium intake [22, 23]. This increase in fecal potassium excretion is likely due to enhanced potassium secretion from the colon [24]. Experimental studies using animal models of CKD have shown that potassium secretion is increased in the colon but not in the small intestine [25]. Rectal dialysis has consistently shown that rectal potassium secretion is increased in patients with ESKD [26, 27]. Of importance, the clinical significance of gastrointestinal potassium secretion in advanced CKD has been highlighted by a recent study showing that time-varying laxative use was associated with lower risk of hyperkalemia in advanced CKD [28]. The role of colonic potassium secretion in ESKD has also been illustrated through a case of an MHD patient with treatment-resistant hyperkalemia associated with colon diversion surgery [29].

As for the mechanism of colonic potassium excretion, BK channel at the apical membrane [30–32], along with Na-K-2Cl cotransporter 1 (NKCC1) and Na/K-ATPase at the basolateral membrane [33–35], is considered to play a major role. In particular, mice-lacking BK channel has reduced potassium content in their feces [31], and this channel is shown to be increased in colonocytes and crypt cells in ESKD patients compared to individuals with normal renal function [36].

The upstream signaling that increases BK channel in the colon is not entirely clear. Changes in serum potassium levels have been suggested as a potential mechanism [37], and it is also possible that MR in the distal colon, which mediates a part of the electrolyte action of...
aldosterone [38, 39], is involved. Previous studies have shown that aldosterone promotes potassium secretion that is inhibited by iberiotoxin, a BK channel blocker, in rodent colonic mucosa [32]. In addition, it has been recently shown that an MR antagonist spironolactone increases serum potassium levels in MHD patients [40], a finding consistent with the role of MR in regulating colonic potassium secretion in ESKD patients.

Besides the kidney and the gastrointestinal system, excretion of electrolytes can occur from the skin. Several lines of evidence indicate the role of the skin in body sodium handling in hypertensive and ESKD patients [41, 42]. Multiple ion channels and transporters are present in the eccrine sweat glands, and a few studies have suggested that the sweat electrolyte composition, including potassium concentration, can be altered in advanced CKD patients [43, 44]. The potential benefit of exercised-induced diaphoresis in ESKD patients as an adjunct treatment has also been discussed [45, 46].

### 3.3 Total body potassium content

Because only a limited portion of potassium is present in extracellular fluid, frequent observation of hyperkalemia in MHD patients does not necessarily mean that the total body potassium content is increased in these patients. In a previous study that determined the total mineral content in the body, Bilbrey et al. reported that total sodium content in the skeletal muscle of ESKD patients increased, whereas the total potassium content decreased compared with that in healthy individuals [47]. Similarly, in an autopsy study involving 24 patients undergoing hemodialysis, Butkus et al. reported that both skeletal muscle and myocardium had lower potassium content than the control group with no history of kidney disease [48]. Many other studies have evaluated body potassium levels in ESKD patients using the naturally occurring isotope $^{40}$K, or by an isotope dilution technique using $^{42}$K; these studies, overall, demonstrated either a decrease or no change in total potassium levels [49]. These studies suggest that hyperkalemia and intracellular potassium deficiency can coexist in a subpopulation of MHD patients. Factors that influence intracellular potassium storage, such as DM, acid/base disorders, and reduced muscle mass, may contribute to the disturbance [5, 46, 50].

### 3.4 Changes in body potassium distribution

Comorbid conditions such as DM can significantly alter potassium distribution in the body. Clinical studies have shown that DM is associated with hyperkalemia both in patients with non-dialysis-dependent CKD and in MHD patients [5], which can be explained by the reduced tissue sensitivity to insulin and impaired cellular glucose uptake. Uremia in ESKD patients can also impair intracellular potassium shift through several mechanisms, such as altered responses to insulin and to catecholamine. Indeed, several studies demonstrated that uremia causes insulin resistance in advanced CKD patients [51, 52]. In addition, there are several studies suggesting that β-adrenergic receptor responsiveness is attenuated in uremic states [53]. In MHD patients, the response to isoprenaline, a non-selective β-adrenergic receptor agonist, is significantly reduced compared with healthy volunteers [54]. Experimental studies showed a selective reduction in β-adrenergic receptor-mediated adenylyl cyclase in the rat remnant model, indicating that the receptor is uncoupled from the downstream signaling mechanism in renal dysfunction [54, 55].

Metabolic acidosis frequently accompanies ESKD, which also contributes to the occurrence of hyperkalemia by preventing intracellular potassium shift. Previous studies have shown that the low serum bicarbonate levels were associated with increased serum potassium levels in non-dialysis-dependent CKD patients [5]. The significance in MHD patients seems less clear, given that no association was found between serum potassium and serum bicarbonate levels in MHD patients [5].

### 4 Association between serum potassium levels and mortality in MHD patients

Abnormal serum potassium levels are associated with all-cause mortality. Goyal et al. conducted a retrospective study of 38,689 patients with acute myocardial infarction and reported a U-shaped relationship between serum potassium levels and in-hospital deaths [56]. In this study, the odds ratio for mortality was lowest in patients with the serum potassium levels of 3.5–4.5 mmol/L, and it was significantly higher in those with serum potassium levels either ≥4.5 mmol/L or < 3.5 mmol/L [56]. In CKD patients, Luo et al. analyzed 55,266 subjects with estimated glomerular filtration rate (eGFR) < 60 ml/min per 1.73 m² and found that the adjusted mortality incidence rate ratios in CKD patients with serum potassium levels < 3.5 mmol/L and those with levels ≥ 6 mmol/L were more than three times higher than the reference group (4.5–4.9 mmol/L) [57]. Kashihara et al. analyzed the association between serum potassium levels and prognosis using a 10-year Japanese hospital claims database [3]. In this analysis, three-year mortality was lowest at 4.0 mmol/L, with a U-shaped association between serum
The clinical characteristics of patients who had arrhythmic risk of increased serum-to-dialysate potassium gradient has been highlighted by an early study that described the clinical characteristics of patients who had cardiac arrest while in the dialysis center [64]. In this study, a low (1 or 0 mEq/L) potassium dialysate was prescribed for 17.1% of case patients, compared with only 8.8% in controls [64]. A recent study has also shown that a high serum-to-dialysate potassium gradient is associated with electrocardiography changes, such as ST changes, QT interval dispersion, and ventricular events during 12-h post hemodialysis [65].

5 | POTASSIUM MANAGEMENT IN MHD PATIENTS

5.1 | Dietary potassium intake

Given the previous studies showing that the majority of hyperkalemic episodes were temporally related to excessive potassium intake [66], and that the magnitude of serum potassium elevation in response to acute potassium loading was higher in ESKD patients than in healthy individuals [67], an increase in potassium intake that surpasses the output increases the risk of hyperkalemia, especially during the long dialysis interval. However, previous studies have shown a modest or no correlation between average dietary potassium intake and pre-dialysis serum potassium levels, suggesting that there is considerable inter-individual variation [5, 68]. In the study by Noori et al., potassium intake was evaluated using the food frequency questionnaire (FFQ), and there was a weak correlation (r = 0.14) between dietary potassium and serum potassium concentrations (which was a mean value of routine laboratory measurements for 3 months) [68]. Ramos et al. measured fasting serum potassium levels and average three-day potassium intake in 95 non-dialysis-dependent CKD patients and 117 MHD patients [5]. The study did not find a significant association between dietary potassium levels (g/1000 kcal/day) and serum potassium levels in either hemodialysis or non-dialysis-dependent CKD patients. In a multivariable analysis, factors associated with hyperkalemia in non-dialysis-dependent CKD patients were DM and metabolic acidosis whereas those in MHD patients were DM and serum creatinine levels [5]. Similarly, the three-day mean potassium intake (mg/kcal) and serum potassium levels had no significant correlation in MHD patients in the BalanceWise study [69].

It remains inconclusive how the variation in dietary potassium intake affects mortality in ESKD patients. In a retrospective analysis by Noori et al. involving 224 MHD patients, high dietary potassium intake was associated with an increased hazard ratio of death in the adjusted model [68]. In a recent prospective cohort of 415 MHD patients, however, Narasaki et al. found that the subjects...
with the lowest tertile of potassium intake had higher mortality than those with the highest tertile even after adjustment for laboratory and nutritional covariates (adjusted hazard ratio of 2.65) [70]. Several studies have also addressed the significance of plant-based diet (such as fruits, vegetables, nuts, and beans) in MHD patients. Gonzalez-Ortiz et al. evaluated whether a plant-based diet was associated with serum potassium levels and nutritional status in 150 HD patients [71]. They used a healthy plant-based diet score (HPDS), which evaluates plant-derived foods positively and animal-derived foods and sugar negatively. In this study, high HPDS levels were not associated with elevated serum potassium levels, nor were there significant differences in dietary potassium density. HPDS was associated with low protein intake and a reduction in the malnutrition inflammatory score [71]. In another study, Saglimbene et al. examined the association between fruit and vegetable intake and mortality in 8078 participants of the dietary intake, death, and hospitalization in adults with ESKD treated with hemodialysis (DIET-HD) study, which is a prospective cohort study [72]. They found no difference in baseline serum potassium levels among the three groups divided according to fruit and vegetable intake, and that the hazard ratio of all-cause mortality in the highest and middle tertiles, of serving per week, was 0.80 (95% CI, 0.71–0.91) and 0.90 (95% CI, 0.81–1.00), respectively, compared with the lowest tertile group. Therefore, in this study, high fruit and vegetable intake was associated with lower mortality rates.

Although plant-based diets are often restricted in hyperkalemic ESKD patients, other dietary sources of potassium also need to be considered. For example, in the abovementioned study by Noori et al., the top five sources of dietary potassium were beef, chicken, Mexican food (such as burritos and enchiladas), hamburgers, and legumes [68]. In addition, dietary potassium content can be influenced by food additives [73, 74], and elderly MHD patients are shown to consume more processed food than non-CKD elderly individuals of the same age [75]. Another point that must be considered is that the plant-based diet is rich in dietary fiber, which positively influences microbiota and intestinal function, and bicarbonate precursors, such as citrate and acetate. In addition, excessive potassium restriction may paradoxically increase potassium absorption in the intestinal tract [76]. Thus, although dietary potassium restriction is generally recommended in CKD patients with hyperkalemia and in MHD patients, the target dietary potassium levels may need to be adjusted on a case-by-case basis according to the patients’ medical conditions, nutritional status, and serum potassium levels [77, 78].

### 5.2 Pharmacological treatment of hyperkalemia

Potassium-binding resins are commonly used for the management of hyperkalemia in MHD patients, and the prescription rate across countries is reported to be 20% in international studies [79]. However, the rate varies in different countries, ranging from 5% to 60% [1, 79]. ESKD patients have a compensatory increase in colonic potassium secretion, and the use of potassium binders seems to be a rational approach. Sodium polystyrene sulfonate (SPS) (and calcium polystyrene sulfonate in a few countries) has mainly been used as a potassium binder for the past 60 years. Polystyrene sulfonate, administered as a sodium salt or calcium salt, adsorbs potassium in exchange for sodium or calcium in the intestinal tract.

In a study of 32 patients with acute or chronic renal failure, the average decrease in serum potassium levels 24 h after oral SPS administration was 1.0 mmol/L [80]. A recent retrospective study also confirmed that SPS reduces serum potassium levels by 0.9 mmol/L [81]. Nonetheless, the use of SPS is associated with gastrointestinal adverse events [82, 83]. In recent years, two new potassium binders, such as patiromer and sodium zirconium cyclosilicate (SZC), have been developed, and accumulating clinical evidence suggests their use as a therapeutic option in hyperkalemic MHD patients.

Patiromer is a non-absorbable potassium-exchange resin that contains a calcium-sorbitol counterion [84]. Patiromer binds potassium in the colon and reduces serum potassium levels within 7 h [85]. Patiromer does not contain sodium, and calcium is released in exchange for potassium. Clinical evidence indicates that patiromer is effective in controlling hyperkalemia in patients with heart failure and non-dialysis-dependent CKD patients for up to 8 or 52 weeks, and its use is associated with a higher proportion of patients on RAAS inhibitors [86–89]. In the Spironolactone With Patiromer in the Treatment of Resistant Hypertension in CKD (AMBER) study, the use of patiromer enabled continued use of spironolactone in CKD patients (eGFR 25–45 ml/min per 1.73 m²) with uncontrolled resistant hypertension [90].

Several clinical studies have tested the efficacy of patiromer in MHD patients [91, 92]. In a study by Bushinsky et al., 12.6 g of patiromer per day (4.2 g three times daily) for a week decreased serum potassium levels by up to 0.6 mmol/L in six MHD patients [91]. Kovesdy et al. performed a retrospective analysis using electronic health record data from MHD patients and reported a decrease in a serum potassium concentration of 0.5 mmol/L after the use of patiromer [93]. Amdur et al. evaluated serum and fecal potassium levels in 27 anuric MHD patients.
with hyperkalemia [92]. In this study, participants received patiromer (16.8 g daily) for 12 weeks after 2 weeks without treatment, followed by 6 weeks of no treatment. Patiromer reduced serum potassium levels from 5.7 to 5.1 mmol/L, and serum potassium levels rebounded to 5.4 mmol/L post-treatment. Stool potassium significantly increased during the treatment phase and decreased significantly after the end of treatment, confirming that patiromer promotes intestinal excretion of potassium [92].

The observed adverse effects of patiromer include reduced serum magnesium levels and gastrointestinal symptoms (such as constipation, nausea, and diarrhea). The occurrence of hypomagnesemia (3%–7%) [86, 87] may be due to the adsorption of cations, such as magnesium in addition to potassium. The decrease in serum magnesium levels was also observed in MHD patients, and the monitoring of serum magnesium levels is recommended especially in cases with an increased risk of arrhythmia [92].

Calcium released from patiromer can in theory bind phosphorus, reducing its absorption in the intestine. Bushinsky et al. found that patiromer reduced serum phosphorus levels from 7.0 to 6.2 mg/dl, supporting this possibility [91]. On the other hand, no obvious changes in serum phosphorus levels were observed in another study [92]. Although the reason for this difference is unclear, it may be related to the difference in the administration regimen of patiromer and the concomitant use of phosphate binders.

Another new potassium binder, SZC, is a non-absorbable inorganic crystal that selectively adsorbs potassium ions in exchange for hydrogen or sodium ions. Several clinical trials to date have shown that SZC is effective in controlling hyperkalemia. In a phase-III study involving hyperkalemic patients (serum potassium levels of 5.0–6.0 mmol/L), SZC dose dependently reduced serum potassium at the initial phase (up to 0.7 mmol/L at 48 h) [94]. In the 12-day maintenance phase, serum potassium levels were maintained at 4.7 and 4.5 mmol/L in the SZC 5 g per day group and 10 g per day group, respectively, compared with >5.0 mmol/L in the placebo group [94]. Similarly, in the Hyperkalemia Randomized Intervention Multidose ZS-9 Maintenance (HARMONIZE) trial, SZC reduced serum potassium levels to normal levels within 48 h in outpatients with hyperkalemia, and a higher proportion of patients remained in the state of normokalemia in SZC groups compared with placebo group [95]. The long-term efficacy of SZC was confirmed in a 12-month phase-III study, and normokalemia was maintained in the majority of patients without dose adjustment of RAAS inhibitors [94]. Adverse events related to SZC included edema and hypokalemia in the HARMONIZE study [95].

The efficacy of SZC in MHD patients was evaluated in the phase-IIIb, multicenter, prospective, randomized, double-blind, placebo-controlled study to reduce incidence of pre-dialysis hyperkalemia With SZC (DIALIZE) trial [96]. This study included 196 MHD patients with hyperkalemia (pre-dialysis serum potassium levels of >5.4 mmol/L), who received 5 g of placebo or SZC daily on non-dialysis days, which was adjusted (maximum 15 g) to achieve normokalemia. In this study, the proportion of patients who maintained pre-dialysis serum potassium of 4.0–5.0 mmol/L was 41% (40 of 97) in the SZC group, compared with 1% (1 of 99) in the placebo group. The proportion of patients requiring rescue therapy to lower potassium was 5.1% (5 of 99) in the placebo group and 2.1% (2 of 97) in the SZC group. Intradialytic weight gain and rates of serious adverse events were similar between the two groups. The results of these interventional studies (summarized in Table 2) indicate that new potassium binders are effective in controlling pre-dialysis potassium levels, and may allow fewer restrictions on dietary potassium intake in MHD patients.

### 5.3 Dialysate potassium concentrations

Another important option for optimal potassium management is to modify the dialysate potassium concentration. Whereas excess potassium that accumulated in the body needs to be efficiently removed, acute changes in serum potassium levels and severe post-dialysis hypokalemia can adversely affect mortality [63, 64]. Evidence suggests that a high serum-to-dialysate potassium gradient is associated with short-term hospitalization [97]. In the phase-5 DOPPS study (2012–2015), the most common prescription was 2.0–2.5 mmol/L of dialysate potassium, although the concentrations of prescribed dialysate potassium considerably vary per country [98]. For example, a dialysate potassium concentration of ≥ 3.0 mmol/L was used in 75% of patients in Germany, whereas a concentration of 2.0 mmol/L was uniformly used in Japan. The concentrations of 1.0–1.5 mmol/L were used in 62% of patients in Spain [98].

Several studies have evaluated the optimal dialysate potassium concentration. In one study, the use of dialysate with ≥3 mmol/L of potassium in patients with hyperkalemia (≥5 mmol/L) was associated with increased mortality after full multivariable adjustment [58]. In another study, the use of low potassium dialysate (<2 mmol/L) was associated with sudden cardiac arrest within dialysis facilities [99]. In this case–control study, the probability of sudden cardiac arrest with the use of dialysate potassium <2 mmol/L was higher when pre-dialysis potassium levels were lower [99]. Using the DOPPS data of 37 765
participants in 12 countries, Jadoul et al. analyzed the association between several clinical practices with sudden death and reported that the sudden death rate was higher for dialysis potassium ≤1.5 or 2–2.5 mmol/L compared with ≥3 mmol/L (hazard ratio, 1.39 for ≤1.5 mmol/L and 1.17 for 2–2.5 mmol/L) [100]. However, in a study that compared all-cause mortality and arrhythmia composite outcomes between the two most commonly used dialysate potassium prescriptions (2 vs. 3 mmol/L), the differences in the outcomes between the two dialysate potassium prescriptions were not significant [98]. Hazard ratios for all-cause mortality were in the range of 0.94–1.03 across four subgroups with the pre-dialysis serum levels of <4.0, 4.0–5.0, 6.1–6.0, and > 6.0 mmol/L [98].

In a recent report by Mercadal et al., the relationship between dialysate potassium prescription and prognosis was examined using 25,629 French Renal Epidemiology and Information Network (REIN) registry data [101]. More than 90% of the institutions used two or more potassium concentration dialysates, and the combination of 2 and 3 mmol/L was the most common (40%), followed by that of three dialysate prescriptions (<2, 2, and 3 mmol/L; 37%). The dialysis units that used the two and three dialysate formula had adjusted mortality hazard ratios of 0.91 (95% CI 0.82–1.01) and 0.84 (95% CI 0.75–0.93), respectively, compared with those using a single dialysate formula [101]; this result indicates the potential benefit of increased diversity in the dialysate potassium prescriptions.

### 5.4 Other factors

Other modifiable factors that can influence serum potassium levels in MHD patients include the gastrointestinal function, acid/base balance, glycemic control, and medications that alter serum potassium levels. The use of RAAS inhibitors is associated with changes in serum potassium levels even in MHD patients especially at a higher dose [40, 102, 103], likely through attenuating extra-renal potassium excretion. A recent study demonstrated that the laxative use was associated with the reduced risk of hyperkalemia in advanced CKD [28], underscoring the importance for the control of constipation.

### 6 Future perspective

This article reviewed the literature on the factors affecting potassium homeostasis and summarized the current evidence on the management of potassium in MHD patients. Regarding the modalities to maintain potassium balance in MHD patients, we consider there are several important areas that need further evaluation. First, it remains to be determined whether strict potassium restriction (such as 1500–2000 mg of daily potassium intake) should be applied, or whether more liberalized diet with an aid of potassium binders is favorable in MHD patients. In the management of phosphate balance, studies have shown that prescribed phosphate restriction was associated

---

**Table 2** Intervventional studies that evaluated the effects of patiromer and SZC in MHD patients

| Study (year) | N | Patient characteristics | Medication (dose) | Study design | Outcome |
|-------------|---|-------------------------|-------------------|--------------|---------|
| Bushinsky et al. (2016) | 6 | MHD patients with the serum potassium levels of 5.5 mmol/L or higher | Patiromer (12.6 g/day) | Pretreatment period for 1 week and patiromer treatment period for 1 week | Maximal decrease of serum potassium was 0.6 mmol/L and fecal potassium excretion increased by 58% in the treatment period |
| Amdur et al. (2020) | 27 | Anuric MHD patients with the predialysis serum potassium levels of 5.1 mmol/L or higher on more than two occasions | Patiromer (16.8 g/day) | Two weeks of no intervention, 12 weeks of patiromer treatment, and 6 weeks of no treatment | Mean potassium levels decreased by 0.6 mmol/L during treatment period and rebounded post-treatment; stool potassium levels significantly increased during the treatment period |
| Fishbane et al. (2019) | 196 | MHD patients with the predialysis serum potassium levels of >5.4 mmol/L after the long interdialytic interval and > 5.0 mmol/L after one short interdialytic interval | SZC (5–15 g/day) | A randomized, double blind, placebo-controlled study consisting of eight-week treatment period and two-week follow-up period | 41.2% in SZC group maintained the predialysis serum potassium levels of 4.0–5.0 mmol/L during four-week stable-dose evaluation period, as compared with 1.0% in placebo group |

Abbreviations: MHD, maintenance hemodialysis; SZC, sodium zirconium cyclosilicate.
with poorer indices on nutritional status and did not improve survival in MHD patients [104]. It has also been reported that treatment with a phosphate binder was associated with a better nutritional status and improved survival [105]. Although studies, indicate that the serum potassium levels of 5.6 mmol/L or higher are associated with increased mortality in MHD patients, there has been a weak or no correlation between average pre-dialysis serum potassium concentrations and mean dietary potassium levels [5, 58, 68]. A plant-based diet has also been shown to be associated with reduced malnutrition score and all-cause mortality [72]. Given the advent of new potassium binding agents, future studies that determine the optimal amounts and sources of dietary potassium, as well as the role of adjunctive use of potassium binders (on-demand use, every other day dosing, etc.), would be helpful.

Second, there still seems to be room for improvement in potassium control during hemodialysis treatment. Although there are no randomized controlled data that show the best dialysate prescription, recent studies indicate a potential benefit of adjusting dialysate potassium prescription depending on patients’ conditions [98]. The optimized approaches to safely and effectively remove potassium during hemodialysis, as well as the risk and benefit of personalized interventions, need to be evaluated in future studies.

Finally, it is unclear whether hyperkalemic HD patients would benefit from continued use of angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). Several recent studies have shown that discontinued ACE inhibitor or ARBs therapy was associated with a higher risk of mortality and cardiovascular events in advanced CKD patients (eGFR < 30 ml/min per 1.73 m²) [106, 107]. Interestingly, a recent case–control study involving 8229 MHD patients has shown that the use of ARBs, but not of ACE inhibitors, was associated with lower all-cause mortality rate [108]. Thus, although the use of RAAS inhibitors can increase the risk of hyperkalemia even in anuric MHD patients [40, 102], the benefit of stopping ACE inhibitors and ARBs in controlling serum potassium levels needs to be balanced against the risk of cardiovascular diseases in MHD patients. Similarly, previous studies have addressed the possible cardiovascular protective effects of MR antagonists in CKD requiring dialysis, and a very recent meta-analysis concluded that MR antagonists probably reduces the risk of all-cause and cardiovascular death in this population [109]. Large ongoing clinical trials [110, 111] will hopefully provide solid evidence on the protective effects, as well as the effects on serum potassium levels, of MR antagonists in ESKD patients.

ACKNOWLEDGMENTS
This work was supported in part by JSPS KAKENHI grants (19H03678).

CONFLICT OF INTEREST
Shigeru Shibata has received honoraria, consulting fees, and/or research support from AstraZeneca, Bayer, Chugai Pharmaceutical, Daiichi Sankyo, Fuji Yakuhin Company, Kowa Company, Kyowa Kirin, Mochida Pharmaceutical Company, MSD, Sanwa Kagaku Kenkyusho, Teijin Pharma, and Torii Pharmaceutical Company, all outside the submitted work. Shunya Uchida has received honoraria and/or consulting fees from Fuji Yakuhin Company, Kowa Company, Mochida Pharmaceutical Company, Sanwa Kagaku Kenkyusho, Teijin Pharma, and Torii Pharmaceutical Company.

ORCID
Shigeru Shibata https://orcid.org/0000-0002-6868-0626

REFERENCES
1. Rossignol P, Lamiral Z, Frimat L, et al. Hyperkalaemia prevalence, recurrence and management in chronic haemodialysis: a prospective multicentre French regional registry 2-year survey. Nephrol Dial Transplant. 2017;32(12):2112–8.
2. Thomsen RW, Nicolaisen SK, Hasvold P, et al. Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes—a Danish population-based cohort study. Nephrol Dial Transplant. 2018;33(9):1610–20.
3. Kashiwara N, Kojsaka S, Kanda E, Okami S, Yajima T. Hyperkalemia in real-world patients under continuous medical care in Japan. Kidney Int. 2019;86(4):1248–60.
4. Jain N, Kotla S, Little BB, et al. Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol. 2012;109(10):1510–3.
5. Ramos CI, Gonzalez-Ortiz A, Espinoso-Cuevas A, Avesani CM, Carrero JJ, Cuppari L. Does dietary potassium intake associate with hyperkalemia in patients with chronic kidney disease? Nephrol Dial Transplant. 2020. https://doi.org/10.1093/ndt/gfaa232. Epub ahead of print.
6. Bakris GL, Siemons M, Richardson D, et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int. 2000;58(5):2084–92.
7. Thomsen RW, Nicolaisen SK, Adelborg K, et al. Hyperkalemia in people with diabetes: occurrence, risk factors and outcomes in a Danish population-based cohort study. Diabet Med. 2018;35(8):1051–60.
8. Shibata S. 30 years of the mineralocorticoid receptor: mineralocorticoid receptor and NaCl transport mechanisms in the renal distal nephron. J Endocrinol. 2017;234(1):T35–47.
9. Ellison DH, Terker AS, Gamba G. Potassium and its discontents: new insight, new treatments. J Am Soc Nephrol. 2016;27(4):981–9.
10. Carrizoza-Gaytan R, Ray EC, Flores D, et al. Intercalated cell BKalpha subunit is required for flow-induced K+ secretion. JCI Insight. 2020;5(8:e130553.
11. Hoorn EJ, Zietse R. Gut-kidney kaliuretic signaling: looking forward to feeding. Kidney Int. 2015;88(6):1230–2.
12. Aburto NJ, Hanson S, Gutierrez H, Hooper L, Elliott P, Cappuccio FP. Effect of increased potassium intake on
cardiovascular risk factors and disease: systematic review and meta-analyses. BMJ. 2013;346:f3178.

13. Vinceti M, Filippini T, Crippa A, de Sesmaisons A, Wise LA, Orsini N. Meta-analysis of potassium intake and the risk of stroke. J Am Heart Assoc. 2016;5(10):e004210.

14. Mente A, O’Donnell MJ, Rangarajan S, et al. Association of urinary sodium and potassium excretion with blood pressure. N Engl J Med. 2014;371(7):601–11.

15. Fujita T, Sato Y. Changes in renal and central noradrenergic activity with potassium in DOCA-salt rats. Am J Physiol. 1984;246(5 Pt 2):F670–5.

16. Raij L, Luscher TF, Vanhoutte PM. High potassium diet augments endothelium-dependent relaxations in the Dahl rat. Hypertension. 1988;12(6):562–7.

17. Zhou MS, Kosaka H, Yoneyama H. Potassium augments vascular relaxation mediated by nitric oxide in the carotid arteries of hypertensive Dahl rats. Am J Hypertens. 2000;13(6 Pt 1):666–72.

18. Pun PH, Middleton JP. Dialysate potassium, dialysate magnesium, and hemodialysis risk. J Am Soc Nephrol. 2017;28(12):3441–51.

19. Basile C, Libutti P, Lisi P, et al. Ranking of factors determining potassium mass balance in bicarbonate haemodialysis. Nephrol Dial Transplant. 2015;30(3):505–13.

20. Blumberg A, Roser HW, Zehnder C, Muller-Brand J. Plasma potassium in patients with terminal renal failure during and after haemodialysis; relationship with diabetic potassium removal and total body potassium. Nephrol Dial Transplant. 1997;12(8):1629–34.

21. Hung AM, Hakim RM. Dialysate and serum potassium in hemodialysis. Am J Kidney Dis. 2015;66(1):125–32.

22. Hayes CP Jr, Robinson RR. Fecal potassium excretion in patients on chronic intermittent hemodialysis. Trans Am Soc Artif Intern Organs. 1965;11:242–6.

23. Hayes CP Jr, McLeod ME, Robinson RR. An extrarenal mechanism for the maintenance of potassium balance in severe chronic renal failure. Trans Assoc Am Physicians. 1967;80:207–16.

24. Sandle GI, Hunter M. Apical potassium (BK) channels and enhanced potassium secretion in human colon. QJM. 2010;103(2):85–9.

25. Bastl C, Hayslett JP, Binder HJ. Increased large intestinal secretion of potassium in renal insufficiency. Kidney Int. 1977;12(1):9–16.

26. Sandle GI, Gaiger E, Tapster S, Goodship TH. Enhanced rectal potassium secretion in chronic renal insufficiency: evidence for large intestinal potassium adaptation in man. Clin Sci (Lond). 1986;71(4):393–401.

27. Sandle GI, Gaiger E, Tapster S, Goodship TH. Evidence for large intestinal control of potassium homoeostasis in uremic patients undergoing long-term dialysis. Clin Sci (Lond). 1987;73(3):247–52.

28. Sumida K, Dashputre AA, Potukuchi PK, et al. Laxative use and risk of Dyskalemia in patients with advanced CKD transitioning to dialysis. J Am Soc Nephrol. 2021;32(4):950–9.

29. Kononowa N, Dickenmann MJ, Kim MJ. Severe hyperkalemia following colon diversion surgery in a patient undergoing chronic hemodialysis: a case report. J Med Case Reports. 2013;7:207.
49. Mitch WE, Wilcox CS. Disorders of body fluids, sodium and potassium in chronic renal failure. Am J Med. 1982;72(3):536–50.

50. Wouda RD, Vogt L, Hoorn EJ. Personalizing potassium management in patients on haemodialysis. Nephrol Dial Transplant. 2021;36(1):13–8.

51. DeFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J. Insulin resistance in uremia. J Clin Invest. 1981; 67(2):563–8.

52. Kobayashi S, Maejima S, Ikeda T, Nagase M. Impact of dialysis therapy on insulin resistance in end-stage renal disease: comparison of haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 2000;15(1):65–70.

53. Mann JF, Hausen M, Jacobs KH, et al. Adrenergic responsiveness in experimental uremia. Contrib Nephrol. 1984;41:108–12.

54. Dhein S, Rohnert P, Markau S, et al. Cardiac beta-adrenoceptors in chronic uremia: studies in humans and rats. J Am Coll Cardiol. 2000;36(2):608–17.

55. Leineweber K, Heinroth-Hoffmann I, Ponicke K, Abraham G, Osten B, Brodde OE. Cardiac beta-adrenoceptor desensitization due to increased beta-adrenoceptor kinase activity in chronic uremia. J Am Soc Nephrol. 2002;13(1):117–24.

56. Goyal A, Spertus JA, Gosch K, et al. Serum potassium levels and mortality in acute myocardial infarction. JAMA. 2012;307(2):157–64.

57. Luo J, Brunelli SM, Jensen DE, Yang A. Association between serum potassium and outcomes in patients with reduced kidney function. Clin J Am Soc Nephrol. 2016;11(1):90–100.

58. Kovesdy CP, Regidor DL, Mehrotra R, et al. Serum and dialysate potassium concentrations and survival in hemodialysis patients. Clin J Am Soc Nephrol. 2007;2(5):999–1007.

59. Hwang JC, Wang CT, Chen CA, Chen HC. Hypokalemia is associated with increased mortality rate in chronic hemodialysis patients. Blood Purif. 2011;32(4):254–61.

60. Yusuf AA, Hu Y, Singh B, Menoyo JA, Wetmore JB. Serum potassium levels and mortality in hemodialysis patients: a retrospective cohort study. Am J Nephrol. 2016;44(3):179–86.

61. Dashputre AA, Potukuchi PK, Sumida K, et al. Predialysis potassium variability and postdialysis mortality in patients with advanced CKD. Kidney Int Rep. 2021;6(2):366–80.

62. Brunelli SM, Du Mond C, Oestreicher N, Rakov V, Spiegel DM. Serum potassium and short-term clinical outcomes among hemodialysis patients: impact of the long interdialytic interval. Am J Kidney Dis. 2017;70(1):21–9.

63. Ohnishi T, Kimachi M, Fukuma S, Akizawa T, Fukuhara S. Postdialysis hypokalemia and all-cause mortality in patients undergoing maintenance hemodialysis. Clin J Am Soc Nephrol. 2019;14(6):873–81.

64. Karnik JA, Young BS, Lew NL, et al. Cardiac arrest and sudden death in dialysis units. Kidney Int. 2001;60(1):350–7.

65. Vareesanathip K, Yinchaoen P, Winijulk A, Chanchairujja T. Cardiac arrhythmia during early-week and mid-week dialysis in hemodialysis patients. Ther Apher Dial. 2021. https://doi.org/10.1111/1744-9987.13622. Epub ahead of print.

66. Tzamaloukas AH, Avasthi PS. Temporal profile of serum potassium concentration in nondiabetic and diabetic outpatients on chronic dialysis. Am J Nephrol. 1987;7(2):101–9.

67. Allon M, Dansby L, Shanklin N. Glucose modulation of the disposal of an acute potassium load in patients with end-stage renal disease. Am J Med. 1993;94(5):475–82.

68. Noori N, Kalantar-Zadeh K, Kovesdy CP, et al. Dietary potassium intake and mortality in long-term hemodialysis patients. Am J Kidney Dis. 2010;56(2):338–47.

69. St-Jules DE, Goldfarb DS, Sevick MA. Nutrient non-equivalence: does restricting high-potassium plant foods help to prevent hyperkalemia in hemodialysis patients? J Ren Nutr. 2016;26(5):282–7.

70. Narasaki Y, Okuda Y, Kalantar SS, et al. Dietary potassium intake and mortality in a prospective hemodialysis cohort. J Ren Nutr. 2021;31(4):411–420.

71. Gonzalez-Ortiz A, Xu H, Ramos-Acevedo S, et al. Nutritional status, hyperkalaemia and attainment of energy/protein intake targets in haemodialysis patients following plant-based diets: a longitudinal cohort study. Nephrol Dial Transplant. 2021;36(4):681–688.

72. Saglimbene VM, Wong G, Ruospo M, et al. Fruit and vegetable intake and mortality in adults undergoing maintenance hemodialysis. Clin J Am Soc Nephrol. 2019;14(2):250–60.

73. Sherman RA, Mehta O. Phosphorus and potassium content of enhanced meat and poultry products: implications for patients who receive dialysis. Clin J Am Soc Nephrol. 2009;4(8):1370–3.

74. Picard K. Potassium additives and bioavailability: are we missing something in hyperkalemia management? J Ren Nutr. 2019;29(4):350–3.

75. Martins AM, Bello Moreira AS, Canella DS, et al. Elderly patients on hemodialysis have worse dietary quality and higher consumption of ultraprocessed food than elderly without chronic kidney disease. Nutrition. 2017;41:73–9.

76. Palmer BF, Clegg DJ. Gastrointestinal potassium binding in hemodialysis. Kidney Int. 2020;98(5):1095–7.

77. Kalantar-Zadeh K, Fouque D. Nutritional management of chronic kidney disease. N Engl J Med. 2017;377(18):1765–76.

78. Cupisti A, Kovesdy CP, D’Alessandro C, Kalantar-Zadeh K. Dietary approach to recurrent or chronic hyperkalaemia in patients with decreased kidney function. Nutrients. 2018;10(3):261.

79. Jadoul M, Karaboysa A, Goodkin DA, et al. Potassium-binding resins: associations with serum chemistries and interdialytic weight gain in hemodialysis patients. Am J Nephrol. 2014;39(3):252–9.

80. Scherr L, Ogden DA, Mead AW, Spritz N, Rubin AL. Management of hyperkalaemia with a cation-exchange resin. N Engl J Med. 1961;264:115–9.

81. Hagan AE, Farrington CA, Wall GC, Belz MM. Sodium polystyrene sulfonate for the treatment of acute hyperkalaemia: a retrospective study. Clin Nephrol. 2016;85(1):38–43.

82. Noel JA, Bota SE, Petricch W, et al. Risk of hospitalization for serious adverse gastrointestinal events associated with sodium polystyrene sulfonate use in patients of advanced age. JAMA Intern Med. 2019;179(8):1025–33.

83. Harel Z, Harel S, Shah PS, Wald R, Perl J, Bell CM. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am J Med. 2013;126(3):264.e9–264.e24.
84. Meaney CJ, Beccari MV, Yang Y, Zhao J. Systematic review and meta-analysis of patiromer and sodium zirconium cyclosilicate: a new armamentarium for the treatment of hyperkalemia. Pharmacotherapy. 2017;37(4):401–11.
85. Palmer BF, Carrero JJ, Clegg DJ, et al. Clinical management of hyperkalemia. Mayo Clin Proc. 2021;96(3):744–62.
86. Pitt B, Anker SD, Bushinsky DA, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011;32(7):820–8.
87. Bakris GL, Pitt B, Weir MR, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA. 2015;314(2):151–61.
88. Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015;372(3):211–21.
89. Pitt B, Bushinsky DA, Kitzman DW, et al. Evaluation of an individual dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease. ESC Heart Fail. 2018;5(3):257–66.
90. Agarwal R, Rossignol P, Romero A, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2019;394(10208):1540–50.
91. Bushinsky DA, Rossignol P, Spiegel DM, et al. Patiromer decreases serum potassium and phosphate levels in patients on hemodialysis. Am J Nephrol. 2016;44(5):404–10.
92. Amdur RL, Paul R, Barrows ED, et al. The potassium regulator patiromer affects serum and stool electrolytes in patients receiving hemodialysis. Kidney Int. 2020;98(5):1331–40.
93. Kovesdy CP, Rowan CG, Conrad A, et al. Real-world evaluation of patiromer for the treatment of hyperkalemia in hemodialysis patients. Kidney Int. 2019;95(4):973–82.
94. Charytan DM, Himmelfarb J, Ikizler TA, et al. Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial. Kidney Int. 2019;95(4):973–82.
95. Movilli E, Camerini C, Gaggia P, Zubani R, Cancarini G. Use of renin-angiotensin system blockers increases serum potassium in anuric hemodialysis patients. Am J Nephrol. 2018;48(2):79–86.
96. Pitt B, Anker SD, Bushinsky DA, et al. Evaluation of the efficacy of spironolactone in dialysis patients receiving lanthanum carbonate. Nephrol Dial Transplant. 2019;34(2):318–25.
97. Qiao Y, Shin JI, Chen TK, et al. Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate. JAMA Intern Med. 2020;180(5):718–26.
98. Fu EL, Evans M, Clase CM, et al. Stopping renin-angiotensin system inhibitors in patients with advanced CKD and risk of adverse outcomes: a nationwide study. J Am Soc Nephrol. 2021;32(2):424–35.
99. Kido R, Akizawa T, Fukagawa M, Onishi Y, Yamaguchi T, Fukuhara S. Interactive effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers or their combination on survival of hemodialysis patients. Am J Nephrol. 2017;46(6):439–47.
100. Hasegawa T, Nishiwaki H, Ota E, Levack WM, Noma H. Aldosterone antagonists for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev. 2021;2:CD013109.
101. Aldosterone Antagonist Chronic HEModialysis Interventional Survival Trial (ALCHEMIST). [cited 2021 Jul 5]. Available from: https://www.clinicaltrials.gov/ct2/show/record/NCT01848639.
102. Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease (ACHIEVE). [cited 2021 Jul 5]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03020303.

How to cite this article: Shibata S, Uchida S. Hyperkalemia in patients undergoing hemodialysis: Its pathophysiology and management. Ther Apher Dial. 2022;26:3–14. https://doi.org/10.1111/1744-9987.13721